Christos Vaklavas, MD, discussed barriers limiting rural oncology access and challenges to adopting resource-intensive therapies.
|Podcasts|March 21, 2023
Health Equity Conversations: Improving Diversity of Oncology Care Staff
Author(s)Matthew Gavidia
On this episode of Managed Care Cast, we feature several leaders in diversity, equity, and inclusion advancing health equity in their respective organization’s policy and practice initiatives.
Advertisement
AJMC.com recently launched a resource center, the
On this episode of Managed Care Cast, we feature several leaders in diversity, equity, and inclusion (DEI) advancing health equity in their respective organization’s policy and practice initiatives, including:
- Terrance Mayes, EdD, associate director for DEI at the Stanford Cancer Institute, and inaugural chair of National Comprehensive Cancer Network's (NCCN) DEI Directors Forum
- Loretta Erhunmwunsee, MD, FACS, thoracic surgeon and an assistant professor in the Division of Thoracic Surgery, City of Hope National Medical Center, and inaugural vice-chair of NCCN's DEI Directors Forum
- Richard L. Martin III, MD, MPH, medical director for Health Equity and Community Engagement, Tennessee Oncology; president, Tennessee Oncology Practice Society.
Advertisement
Related to this article
FDA cut required monitoring for tarlatamab’s first 2 doses from 22-24 hours to 6-8 hours, easing a barrier to community cancer care.
Patient factors and access barriers are reshaping treatment sequencing and individualized care for relapsed multiple myeloma, Amandeep Godara, MBBS, said.
Shiven B. Patel, MD, MBA, shares strategies for closing biomarker testing gaps, including for patients with non–small cell lung cancer.
AI-assisted spirometry, imaging biomarkers, and population screening strategies highlighted early detection and prevention as a throughline at the ERS Congress.
ASCOLT finds no overall adjuvant aspirin benefit in colorectal cancer, but meta-analysis links improved disease-free survival to PIK3CA exon 9/20 mutations.
Community oncology leaders urge 340B overhaul so drug discounts follow vulnerable cancer patients, with audits, transparency, and tighter contract-pharmacy rules. This commentary will be featured on the Cover of the October issue of Evidence-Based Oncology.
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
Advertisement
Advertisement
Trending on AJMC
1
FDA Expands Finerenone Approval to CKD Associated With Type 1 Diabetes
2
Across the US, Obesity Care Still Lacks an Owner
3
GLP-1 Receptor Agonists Cut Ascites, Mortality in MASH
4
Twice-Yearly CD19 Therapy Targets MG Root Cause: Richard Nowak, MD, MS
5